Urogen Pharma (URGN) Stock Price, News & Analysis

Company Overview

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer. UroGen’s development programs and commercial activities primarily serve patients and healthcare providers in the United States, with a focus on urologic oncology.

Key Stats

• Today's Range: $34.00 to $34.97
• 50-Day Range: $32.72 to $46.36
• 52-Week Range: $16.50 to $50.81
• Volume: 1.22 million shs
• Average Volume: 841,417 shs
• Market Capitalization: $1.68 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.38
• Consensus Rating: Moderate Buy

Urogen Pharma Stock Analysis - MarketRank™

Urogen Pharma scored higher than 77% of companies evaluated by MarketBeat, and ranked 137th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Urogen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Urogen Pharma has a consensus price target of $52.38, representing about 52.3% upside from its current price of $34.40.

Amount of Analyst Coverage

Urogen Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Urogen Pharma are expected to grow in the coming year, from ($0.20) to $2.94 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Urogen Pharma is -17.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Urogen Pharma is -17.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.05% of the float of Urogen Pharma has been sold short.

Short Interest Ratio / Days to Cover

Urogen Pharma has a short interest ratio ("days to cover") of 4.93.

Change versus previous month

Short interest in Urogen Pharma has recently decreased by 27.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Urogen Pharma does not currently pay a dividend.

Dividend Growth

Urogen Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.23

News Sentiment

Urogen Pharma has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Urogen Pharma this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

6 people have added Urogen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Urogen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,037,646.00 in company stock.

Percentage Held by Insiders

4.80% of the stock of Urogen Pharma is held by insiders.

Percentage Held by Institutions

91.29% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 11/03/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:URGN
• CIK: 1668243
• Web: www.urogen.com
• Phone: (646) 768-9780
• Fax: N/A
• Employees: 291
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Urogen Pharma: $52.38
• High Price Target: $75.00
• Low Price Target: $33.00
• Potential Upside/Downside: +52.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 11.70
• P/E Growth: N/A
• Net Income: -$153.49 million
• Net Margins: -51.73%
• Pretax Margin: -51.98%
• Return on Equity: N/A
• Return on Assets: -43.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.80
• Quick Ratio: 3.41

Sales & Book Value

• Annual Sales: $109.79 million
• Price / Sales: 15.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.25) per share
• Price / Book: -15.29

Miscellaneous

• Outstanding Shares: 48,880,000
• Free Float: 46,535,000
• Market Cap: $1.68 billion
• Optionable: Optionable
• Beta: 1.57